CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Xtant Medical Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Xtant Medical Holdings Inc
664 Cruiser Lane
Phone: (406) 388-0480p:406 388-0480 BELGRADE, MT  59714  United States Ticker: XTNTXTNT
Business Summary
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Stavros G.Vizirgianakis 54 8/26/2022 8/26/2022
President, Chief Executive Officer, Director Sean E.Browne 59 10/30/2019 10/7/2019
Chief Financial Officer Scott C.Neils 40 6/1/2022 1/3/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Bacterin International Holdings Inc
Bacterin International Holdings Inc.
Bacterin International Holdings, Inc.
13 additional Business Names available in full report.

General Information
Number of Employees: 151 (As of 12/31/2025)
Outstanding Shares: 140,068,260 (As of 3/25/2026)
Shareholders: 162
Stock Exchange: ASE
Federal Tax Id: 205313323
Fax Number: (302) 636-5454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026